All News
Filter News
Found 620 articles
-
Regeneron Completes Secondary Offering of Common Stock Held by Sanofi
5/29/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the secondary offering of 13,014,646 shares of its common stock held by Sanofi, which includes the exercise in full of the underwriters' option to purchase additional shares from Sanofi, at a public offering price of $515.00 per share.
-
Libtayo® (cemiplimab-rwlc) Longer-term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ASCO 2020 Show Durable Responses that Deepen Over Time
5/29/2020
Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up CRs are 20%, nearly tripling with two additional years of follow-up Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced new, longer-term data for PD-1 inhibitor Libtayo ® (cem
-
Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi
5/27/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of the underwritten public secondary offering of 11,831,496 shares of its common stock held by Sanofi at a price of $515.00 per share
-
Heading into the first week after Memorial Day, which in the U.S. marks the typical beginning of summer, the U.S. Food and Drug Administration has a number of drug approvals on the calendar. Here’s a look.
-
To date, Dupixent is the only biologic approved for this age group.
-
Sanofi is selling off its nearly $13 billion in investments in longtime development partner Regeneron as the France-based company shifts its strategy to focus on indications such as oncology, neurology, rare diseases and hematology.
-
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
5/26/2020
In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone
-
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
5/25/2020
Regeneron Pharmaceuticals, Inc. announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi intends to exit its investment in Regeneron shares.
-
Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints
5/22/2020
Dupixent demonstrated significant clinical and anatomic improvements, including the ability to swallow, in Part A of pivotal trial
-
Regeneron Presentations at ASCO 2020 Showcase Diverse Clinical Oncology Portfolio
5/13/2020
Regeneron Pharmaceuticals, Inc. announced the company will share updates from its diverse clinical oncology portfolio at the 2020 American Society of Clinical Oncology Annual Meeting from May 29-31 taking place virtually.
-
Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
5/11/2020
Regeneron Genetics Center will sequence 450,000 informed and consented patients
-
Sanofi and Regeneron are focusing on basal cell carcinoma treatment and their drug Libtayo is showing good results. The companies expect to make regulatory submissions this year.
-
Regeneron Reports First Quarter 2020 Financial and Operating Results
5/5/2020
Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2020 and provided a business update..
-
Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma
5/5/2020
Objective responses seen in approximately 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival
4/27/2020
Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary endpoint of overall survival was met in a Phase 3 trial comparing the PD-1 inhibitor Libtayo® to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer that tested positive for PD-L1 in ≥50% of tumor cells.
-
Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients
4/27/2020
Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced "critical" group with Kevzara higher-dose versus placebo and discontinuing less advanced "severe" group
-
Sanofi at forefront of fight against COVID-19 in Q1 2020
4/24/2020
Sanofi (NASDAQ: SNY; EURONEXT: SAN) Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8719551-sanofi-earnings-results-q1-2020/ Rapid and decisive response to COVID-19 global health crisis Sanofi showed resilience and maintained full business continuity worldwide including it
-
FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola
4/16/2020
REGN-EB3 developed via same rapid response platform currently being leveraged to develop novel COVID-19 antibody therapy
-
Study Finds Number of Asthma Biologic Medication Users and Spend Doubled Over 2.5 Years
4/16/2020
New research from Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 30 million members nationally, found that among commercially insured members with asthma, the number of members who utilized biologics nearly doubled in a 2.5 year span, as did the amount of spending on those medications.
-
Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex
4/15/2020
Evelo Biosciences, Inc. announced the appointment of biopharmaceutical industry veteran Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer and a member of the Evelo Executive Team.